![]() | This article may be unbalanced toward certain viewpoints.(March 2017) |
![]() | |
Clinical data | |
---|---|
Trade names | Entyce, Elura, Eluracat |
Other names | CP-424,391 |
License data |
|
Routes of administration | By mouth |
ATCvet code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 2.4 hours [4] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H35N5O4 |
Molar mass | 505.619 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Capromorelin, sold under the brand names Entyce and Elura, is a medication used for the management of weight loss in cats and dogs. [5] [6] Capromorelin is a ghrelin receptor agonist known to increase appetite and weight gain. [2]
Capromorelin was developed by Pfizer. [7] [8]
Capromorelin was approved for veterinary use in the United States in May 2016. [9] It is the second drug approved for the management of weight loss in cats and the first drug approved specifically for the management of weight loss in cats with chronic kidney disease. [2]
Capromorelin functions to stimulate the secretion of growth hormone and as a ghrelin mimetic which causes the body to secrete human growth hormone in a way usually seen at puberty and in young adulthood. Studies have shown the drug to directly raise insulin growth factor 1 (IGF-1) and growth hormone levels. [10]
In a one-year treatment trial (starting 1999) with 395 seniors between 65 and 84 years old, patients who received the drug gained an average of 3 lb (1.4 kg) in lean body mass in the first six months and also were better able to walk in a straight line in a test of balance, strength and coordination. After 12 months, patients receiving capromorelin also had an improved ability to climb stairs; however, the results were not good enough to continue the trial for the second planned year. [11]
As of 2017, capromorelin studies in humans had been discontinued. [12]
Capromorelin is indicated for the management of weight loss in cats and dogs. [2]